Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 172.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 172.09K shares, a 1045.61% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 89.11K shares, a 62.71% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 316.22K shares, a 14.83% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 275.38K shares, a 4.49% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 263.55K shares.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2018 was 20.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 172.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 172.09K shares 10-Q · filed 2026-08-13 | 172.09K shares derived: sum of 3 quarters · filed 2026-08-13 | 261.20K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-14 | 89.11K shares derived: sum of 3 quarters · filed 2026-05-14 | 104.13K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 89.11K shares derived: sum of 2 quarters · filed 2026-03-19 | 104.13K shares derived: sum of 3 quarters · filed 2026-03-19 | 316.22K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 89.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 104.13K shares derived: sum of 2 quarters · filed 2025-11-06 | 316.22K shares 10-Q · filed 2025-11-06 | 326.88K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 15.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 227.11K shares 10-Q · filed 2025-08-07 | 237.77K shares derived: sum of 3 quarters · filed 2025-08-07 | 476.72K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-03-31 | 212.09K shares 10-Q · filed 2025-05-13 | 222.75K shares derived: sum of 2 quarters · filed 2025-05-13 | 461.70K shares derived: sum of 3 quarters · filed 2025-11-06 | 487.47K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-12-31 | 10.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 249.60K shares derived: sum of 2 quarters · filed 2025-11-06 | 275.38K shares derived: sum of 3 quarters · filed 2025-11-06 | 275.38K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 238.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 264.72K shares derived: sum of 2 quarters · filed 2025-11-06 | 264.72K shares 10-Q · filed 2025-11-06 | |
| 2024-06-30 | 25.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 25.77K shares 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 263.55K shares 10-K · filed 2024-03-14 | |||
| 2023-06-30 | 122.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 183.44K shares 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 61.25K shares 10-Q · filed 2023-05-11 | |||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | 20.00K shares 10-K · filed 2019-03-25 | ||
| 2018-09-30 | 20.00K shares 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |